Press release
Growth Opportunities in the Levobupivacaine Market and Leading Key Vendors (Cellix Bio, UCB, AbbVie, AstraZeneca, Maruishi, Abbott, Pfizer) | Forecast to 2024
Levobupivacaine
Overview of Global Levobupivacaine Market:
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine.
The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Levobupivacaine market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/253583 .
Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Levobupivacaine costs and an increase in the number of production of amino-amide local anaesthetic drug.
Product Type Segmentation:
The Levobupivacaine market have different product type such as Allo 5ML and 10ML. Levobupivacaine market product type gives Levobupivacaine and allows production of amino-amide local anaesthetic drug.
Industry Segmentation:
Increasing instances across various sectors such as Oral Surgery Procedures, Diagnostic And Therapeutic Procedures, Obstetrical Procedures and Other are raising the need of surgical bone replacement device, thereby raising the demand for Levobupivacaine market. This calls for the need of production of amino-amide local anaesthetic drug.
Segmentation by Regions:
The Levobupivacaine market in North America has created a platform for production of amino-amide local anaesthetic drug in the world. The Levobupivacaine market consists of the production of amino-amide local anaesthetic drug. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Levobupivacaine Market during the forecast year.
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global Levobupivacaine Market Report 2020" @ https://www.businessindustryreports.com/buy-now/253583/single .
Top Leading Key Manufacturers are: Cellix Bio, UCB, AbbVie, AstraZeneca, Purdue Pharma, Maruishi, Abbott, Pfizer, Anesiva, Pacira BioSciences, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hengrui Pharmaceutical, Zhuhai Rundu Pharmaceutical. New product launches and continuous technological innovations are the key strategies adopted by the major players.
Top Industry News:
PULMONOMY AND CELLIX BIO ANNOUNCE EXCLUSIVE DEVELOPMENT AGREEMENT FOR ANTI-FUNGAL INHALATION THERAPEUTICS ON MAR. 6, 2020 - Pulmonomy, an inhalation therapeutics-focused subsidiary of TotalClarity, Inc., today announced a collaboration agreement with Cellix Bio for exclusive global rights to develop CLX-159 for the treatment of Invasive Pulmonary Aspergillosis (IPA) and Allergic Bronchopulmonary Aspergillosis (ABPA).
Under the terms of the agreement, Pulmonomy will pay Cellix Bio an upfront research and development funding fee, and potential payments tied to development milestones, assuming successful achievement of specified development, regulatory and commercialization objectives, as well as a tiered royalty on global sales of CLX-159.
Pulmonomy plans to submit an IND application for CLX-159 as a first line treatment for Invasive Pulmonary Aspergillosis and Allergic Bronchopulmonary Aspergillosis to the US FDA in the first quarter of 2021. Under the terms of the agreement, Pulmonomy will undertake and fund future regulatory and commercial activities to bring CLX-159 to market and commercialize the product within the agreement's territories.
"CLX-159 has the potential to become an important new first line treatment for Invasive Pulmonary Aspergillosis (IPA), and we look forward to submitting an IND early next year," said Shekhar Shastri, Chief Executive Officer of TotalClarity, Inc. "As a recently established specialty pharma company, Pulmonomy has ambitious growth plans, and CLX-159 is a strong strategic fit with our pipeline of high-impact drug candidates, especially in the inhalation therapeutics as we expand our focus and capability in pulmonary and infectious disease areas."
"Patients at risk for infection are rising rapidly due to a number of risk factors, predisposing them to Invasive Fungal Infections (IFI). The development program between Cellix Bio and Pulmonomy is aimed at addressing this epidemiological trend," said Dr. Regis DeSilva, Chief Medical Officer of TotalClarity, Inc., the parent company of Pulmonomy.
"Our agreement with Pulmonomy marks a critical step in the execution of our company strategy. We have a solid foundation to potentially generate near-term capital and long-term value for this important asset CLX-159 globally," said Mahesh Kandula, Chief Executive Officer of Cellix Bio. "This CLX-159 partnership would amount to potential payments over the next 18 months in addition to potential payments from our other licensed pipeline assets, which could provide substantial additional funding to support our CLX-159 development strategy for North America. We look forward to working with the experienced commercial and regulatory team at Pulmonomy as they seek to successfully commercialize CLX-159 in North America and Europe."
Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/253583 .
Major Points in Table of Contents:
1 Levobupivacaine Product Definition
2 Global Levobupivacaine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Levobupivacaine Shipments
2.2 Global Manufacturer Levobupivacaine Business Revenue
2.3 Global Levobupivacaine Market Overview
3 Manufacturer Levobupivacaine Business Introduction
3.1 Cellix Bio Levobupivacaine Business Introduction
3.1.1 Cellix Bio Levobupivacaine Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 Cellix Bio Levobupivacaine Business Distribution by Region
3.1.3 Cellix Bio Interview Record
3.1.4 Cellix Bio Levobupivacaine Business Profile
3.1.5 Cellix Bio Levobupivacaine Product Specification
3.2 UCB Levobupivacaine Business Introduction
3.2.1 UCB Levobupivacaine Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 UCB Levobupivacaine Business Distribution by Region
3.2.3 Interview Record
3.2.4 UCB Levobupivacaine Business Overview
3.2.5 UCB Levobupivacaine Product Specification
3.3 AbbVie Levobupivacaine Business Introduction
3.3.1 AbbVie Levobupivacaine Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 AbbVie Levobupivacaine Business Distribution by Region
3.3.3 Interview Record
3.3.4 AbbVie Levobupivacaine Business Overview
3.3.5 AbbVie Levobupivacaine Product Specification
3.4 AstraZeneca Levobupivacaine Business Introduction
3.5 Purdue Pharma Levobupivacaine Business Introduction
3.6 Maruishi Levobupivacaine Business Introduction
................... Request free sample to get a complete Table of Content
About us
BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.
Media Contact
Business Industry Reports
Pune - India
sales@businessindustryreports.com
+19376349940
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Growth Opportunities in the Levobupivacaine Market and Leading Key Vendors (Cellix Bio, UCB, AbbVie, AstraZeneca, Maruishi, Abbott, Pfizer) | Forecast to 2024 here
News-ID: 1988750 • Views: …
More Releases from Business Industry Reports
Tetracaine Market Exhibits a Lucrative Growth Potential during 2021-2025 | Endo …
BusinessIndustryReports has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Tetracaine Market” Research Report 2021 provides an in-depth analysis of the Tetracaine with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house). The research study examines the Tetracaine on the basis of a number of criteria,…
Cyber Warfare Market Evenly Poised To Reach A Market Value of US$ By Share, Size …
Overview of Global Cyber Warfare Market:
This report provides in-depth study of “Global Cyber Warfare Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cyber Warfare Market report also provides an in-depth survey of key players in the market organization.
According to the market research study, the Cyber Warfare is virtual conflict between state, organization, or country by the use of computer technology to disrupt activities…
Covid-19 Impact on Cranio Maxillofacial Implant Market 2021-2025: Business Growt …
Overview of Global Cranio Maxillofacial Implant Market:
This report provides in-depth study of “Global Cranio Maxillofacial Implant Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cranio Maxillofacial Implant Market report also provides an in-depth survey of key players in the market organization.
According to the market research study, Craniomaxillofacial Implants are medical implants used in surgeries of maxillofacial region such as, head, face, neck, oral,…
Beginning of the bloom: The Rise of the Biohacking Market 2021-2025 | Global Key …
Global Biohacking Market Synopsis:
The report covers a forecast and an analysis of the Biohacking Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Biohacking Market along with the impact they have on the demand over the forecast…
More Releases for Levobupivacaine
Levobupivacaine Hydrochloride Injection Market Size, Share and Forecast By Key P …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Levobupivacaine Hydrochloride Injection market is anticipated to grow at a compound annual growth rate (CAGR) of 15.68% between 2024 and 2031. The market is expected to grow to USD 26.07 Billion by 2024. The valuation is expected to reach USD 72.26 Billion by 2031.
The market for levobupivacaine hydrochloride injection is expanding rapidly due to the growing number of surgical procedures and…
Levobupivacaine Hydrochloride Market Set to Expand at a Staggering 7.4% CAGR, Re …
Levobupivacaine hydrochloride, a long-acting local anesthetic, has been gaining significant traction in the medical field owing to its effectiveness and lower cardiotoxicity compared to its racemic counterpart, bupivacaine. This compound is primarily utilized in regional anesthesia for surgeries ranging from orthopedic procedures to obstetrics, showcasing a broad spectrum of applications. As the demand for safer and efficient anesthesia continues to rise, the Levobupivacaine Hydrochloride market is poised for steady growth…
Levobupivacaine Market to Witness Robust Expansion by 2029
Levobupivacaine Market size was valued at USD billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 17.69% from 2024 to 2030. Levobupivacaine has emerged as a cornerstone, revolutionizing patient care and surgical procedures. As the medical landscape evolves, the Levobupivacaine market stands poised for significant growth and innovation, driven by its efficacy, safety profile, and expanding applications across various medical disciplines.
In order to…
Levobupivacaine Hydrochloride Market 2023 | Detailed Report
The Levobupivacaine Hydrochloride research report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company growth. In order to gauge the turning point of the businesses, significant market key players are also enlisted in order to deliver readers with in-depth analysis about industry strategies.
The Levobupivacaine…
Levobupivacaine Market Trends, Market Share, Industry Size, Growth, Opportunitie …
The global levobupivacaine market is anticipated to grow at a CAGR of 3.9% during the forecast period (2022-2028). The demand for levobupivacaine is expected to rise due to an increase in the number of plastic surgeries and other cosmetic operations. The rising use of dental implants and sedation dentistry, as well as the growing global senior population, are some of the factors that will drive market expansion in the approaching…
Global Levobupivacaine Market Regional Outlook 2021|Cellix Bio, UCB, AbbVie
Complete study of the global Levobupivacaine market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Levobupivacaine industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate…
